Related Experiment Video
Updated: Jun 28, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Ultrasound-Triggered Azo Free Radicals for Cervical Cancer Immunotherapy
Yumeng Wang1,2, Bin Lv1,2, Han Wang3
1Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, PR China.
Abstract:
PD-1 blockade is a first-line treatment for recurrent/metastatic cervical cancer but benefits only a small number of patients due to low preexisting tumor immunogenicity. Using immunogenic cell death (ICD) inducers is a promising strategy for improving immunotherapy, but these compounds are limited by the hypoxic environment of solid tumors. To overcome this issue, the nanosensitizer AIBA@MSNs were designed based on sonodynamic therapy (SDT), which induces tumor cell death under hypoxic conditions through azo free radicals in a method of nonoxygen radicals. Mechanistically, the azo free radicals disrupt both the structure and function of tumor mitochondria by reversing the mitochondrial membrane potential and facilitating the collapse of electron transport chain complexes. More importantly, the AIBA@MSN-based SDT serves as an effective ICD inducer and improves the antitumor immune capacity. The combination of an AIBA@MSN-based SDT with a PD-1 blockade has the potential to improve response rates and provide protection against relapse. This study provides insights into the use of azo free radicals as a promising SDT strategy for cancer treatment and establishes a basic foundation for nonoxygen-dependent SDT-triggered immunotherapy in cervical cancer treatment.
Insights
New nanosensitizers induce cancer cell death via sonodynamic therapy (SDT), overcoming tumor hypoxia. This approach enhances anti-PD-1 immunotherapy for cervical cancer, improving treatment response and preventing relapse.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Immunotherapy
Background:
- PD-1 blockade is a first-line treatment for recurrent/metastatic cervical cancer, but limited efficacy is observed due to low tumor immunogenicity.
- Solid tumors' hypoxic environment restricts the effectiveness of immunogenic cell death (ICD) inducers used in immunotherapy.
- Novel strategies are needed to enhance tumor immunogenicity and improve responses to immunotherapy.
Purpose of the Study:
- To design and evaluate a novel nanosensitizer, AIBA@MSNs, for sonodynamic therapy (SDT).
- To investigate the potential of AIBA@MSN-based SDT to induce immunogenic cell death (ICD) under hypoxic conditions.
- To assess the combination of AIBA@MSN-based SDT with PD-1 blockade for improved cervical cancer treatment.
Main Methods:
- Development of AIBA@MSNs, a nanosensitizer utilizing SDT for non-oxygen radical generation.
- Investigation of the mechanism of azo free radicals in disrupting tumor cell mitochondria.
- Evaluation of AIBA@MSN-based SDT as an ICD inducer and its effect on antitumor immunity.
- Assessment of the combined efficacy of AIBA@MSN-based SDT and PD-1 blockade in a preclinical model.
Main Results:
- AIBA@MSNs effectively induce tumor cell death via SDT under hypoxic conditions using azo free radicals.
- Azo free radicals disrupt mitochondrial structure and function, leading to ICD.
- AIBA@MSN-based SDT enhances antitumor immune capacity, acting as an effective ICD inducer.
- Combination therapy of AIBA@MSN-based SDT and PD-1 blockade shows potential for improved treatment response and relapse protection.
Conclusions:
- AIBA@MSN-based SDT offers a promising approach to overcome tumor hypoxia and induce ICD.
- Non-oxygen radical-dependent SDT can enhance immunotherapy efficacy in cervical cancer.
- This strategy provides a foundation for developing novel immunotherapies for challenging cancers.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...